Highlights Newsletter 3

This newsletter presents you the following key sessions:

1. Podcast with Prof. Daniel Petrylak about pembrolizumab plus docetaxel for patients with metastatic
    castration-resistant prostate cancer

2. Podcast with Dr. Matthew D. Galsky about the efficacy and safety of atezolizumab plus platinum/
    gemcitabine for the first-line treatment of locally advanced or metastatic urothelial carcinoma

3. Podcast with Dr. Alan H. Bryce about the survival outcomes of rucaparib vs. docetaxel or second-
    generation androgen pathway inhibitor therapy in mCRPC patients

4. Podcast with Dr. Vadim Koshkin and Tanya Jindal about biomarkers of response to enfortumab
    vedotin in advanced urothelial carcinoma